文献速递肿瘤 PET/CT

68Ga-FAPi-46 PET生物分布与实体瘤患者FAP免疫组化表达的相关性:前瞻性转化探索性研究的中期分析

Correlation of 68Ga-FAPi-46 PET Biodistribution with FAP Expression by Immunohistochemistry in Patients with Solid Cancers: Interim Analysis of a Prospective Translational Exploratory Study.
PubMed 文献 · J Nucl Med · 2021-11-05

本研究通过组织芯片免疫组化筛查泛癌FAP表达,并开展前瞻性探索性影像试验中期分析,15例患者在68Ga-FAPi-46 PET/CT后手术切除。结果显示肿瘤组织SUVmax、SUVmean及FAP免疫组化评分均高于瘤旁非癌组织,且PET SUV与FAP免疫组化评分强相关。

要点

  • 组织芯片中14种癌症均表达FAP,阳性率25%至100%(均值76.6%±25.3%)。
  • 肿瘤组织SUVmax均值7.7 vs 瘤旁非癌组织1.6(P<0.001),SUVmean均值6.2 vs 1.0(P<0.001)。
  • FAP免疫组化评分与SUVmax和SUVmean强相关,r分别为0.781和0.783(P<0.001)。

核心结论

  • 在此前瞻性探索性影像试验的中期分析中,68Ga-FAPi-46 PET在多种癌症中的生物分布与FAP组织表达强相关。
  • 这些发现支持进一步探索FAPi PET作为FAP表达的泛癌影像生物标志物及FAP靶向治疗的 stratification 工具。

研究设计与样本

  • 采用组织芯片对141例患者、14种癌症进行FAP免疫组化表达筛查。
  • 前瞻性探索性影像试验中期分析,15例各种类型癌症患者接受1次全身68Ga-FAPi-46 PET/CT扫描,随后手术切除原发肿瘤或转移灶。

主要发现

  • 组织芯片中FAP在所有14种癌症类型中表达,强度和频率不一,范围25%至100%(均值76.6%±25.3%)。
  • 胆管、膀胱、结肠、食管、胃、肺、口咽、卵巢和胰腺癌中50%-100%的癌症观察到强FAP表达。
  • 15例患者(结直肠癌4例、头颈癌3例、胰腺癌2例、乳腺癌2例、胃癌1例、食管癌2例、子宫癌1例)在68Ga-FAPi-46 PET/CT后平均16.1±14.4天接受手术。
  • 肿瘤组织SUVmax均值7.7 vs 瘤旁非癌组织1.6(P<0.001),SUVmean均值6.2 vs 1.0(P<0.001),FAP免疫组化评分均值2.8 vs 0.9(P<0.001)。
  • FAP免疫组化评分与68Ga-FAPi-46 SUVmax和SUVmean强相关:r=0.781(95%CI 0.376-0.936;P<0.001)和r=0.783(95%CI 0.379-0.936;P<0.001)。

关键数值与推荐

  • 组织芯片FAP表达阳性率范围25%至100%,均值76.6%±25.3%。
  • 肿瘤组织SUVmax均值7.7 vs 瘤旁非癌组织1.6(P<0.001)。
  • 肿瘤组织SUVmean均值6.2 vs 瘤旁非癌组织1.0(P<0.001)。
  • 肿瘤组织FAP免疫组化评分均值2.8 vs 瘤旁非癌组织0.9(P<0.001)。
  • FAP免疫组化评分与SUVmax的相关系数r=0.781(95%CI 0.376-0.936;P<0.001),与SUVmean的r=0.783(95%CI 0.379-0.936;P<0.001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Fibroblast activation protein (FAP)-expressing cancer-associated fibroblasts confer treatment resistance and promote metastasis and immunosuppression. Because FAP is overexpressed in many cancers, radiolabeled molecules targeting FAP are studied for their use as pancancer theranostic agents. This study aimed to establish the spectrum of FAP expression across various cancers by immunohistochemistry and to explore whether 68Ga FAP inhibitor (FAPi)-46 PET biodistribution faithfully reflects FAP expression from resected cancer and non-cancer specimens. Methods: We conducted a FAP expression screening using immunohistochemistry on a pancancer human tissue microarray (141 patients, 14 different types of cancer) and an interim analysis of a prospective exploratory imaging trial in cancer patients. Volunteer patients underwent 1 whole-body 68Ga-FAPi-46 PET/CT scan and, subsequently, surgical resection of their primary tumor or metastasis. 68Ga-FAPi-46 PET SUVmax and SUVmean was correlated with FAP immunohistochemistry score in cancer and tumor-adjacent non-cancer tissues for each patient. Results: FAP was expressed across all 14 cancer types on tissue microarray with variable intensity and frequency, ranging from 25% to 100% (mean, 76.6% ± 25.3%). Strong FAP expression was observed in 50%-100% of cancers of the bile duct, bladder, colon, esophagus, stomach, lung, oropharynx, ovary, and pancreas. Fifteen patients with various cancer types (colorectal [n = 4], head and neck [n = 3], pancreas [n = 2], breast [n = 2], stomach [n = 1], esophagus [n = 2], and uterus [n = 1]) underwent surgery after their 68Ga-FAPi-46 PET/CT scan within a mean interval of 16.1 ± 14.4 d. 68Ga-FAPi-46 SUVs and immunohistochemistry scores were higher in cancer than in tumor-adjacent non-cancer tissue: mean SUVmax 7.7 versus 1.6 (P < 0.001), mean SUVmean 6.2 versus 1.0 (P < 0.001), and mean FAP immunohistochemistry score 2.8 versus 0.9 (P < 0.001). FAP immunohistochemistry scores strongly correlated with 68Ga-FAPi 46 SUVmax and SUVmean: r = 0.781 (95% CI, 0.376-0.936; P < 0.001) and r = 0.783 (95% CI, 0.379-0.936; P < 0.001), respectively. Conclusion: In this interim analysis of a prospective exploratory imaging trial, 68Ga-FAPi-46 PET biodistribution across multiple cancers strongly correlated with FAP tissue expression. These findings support further exploration of FAPi PET as a pancancer imaging biomarker for FAP expression and as a stratification tool for FAP-targeted therapies.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Mona CE, Benz MR, Hikmat F, et al. Correlation of 68Ga-FAPi-46 PET Biodistribution with FAP Expression by Immunohistochemistry in Patients with Solid Cancers: Interim Analysis of a Prospective Translational Exploratory Study. J Nucl Med. 2021. PMID: 34740953. doi:10.2967/jnumed.121.262426

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。